Aarti Pharmalabs Ltd (NSE: AARTIPHARM) and Aether Industries Limited (NSE: AETHER) are both listed in the Pharmaceutical Contract Manufacturing Services industry. Aarti Pharmalabs has a market capitalisation of ₹8,060 Cr and Aether Industries ₹20,196 Cr, as of 9 Nov 2026. Their P/E ratios are 46.2 and 92 respectively. Return on equity is 8.49% for Aarti Pharmalabs and 9.81% for Aether Industries. Over one year, Aarti Pharmalabs's share price is up 7.6% and Aether Industries's is up 108.3%.
| Metric | Aarti Pharmalabs | Aether Industries |
|---|---|---|
| NSE Symbol | AARTIPHARM | AETHER |
| BSE Code | 543748 | 543534 |
| Share Price | ₹923.00 | ₹1,586.60 |
| Market Cap | ₹8,060 Cr | ₹20,196 Cr |
| P/E Ratio | 46.2 | 92 |
| Return on Equity | 8.49% | 9.81% |
| Return on Assets | 5.84% | 6.36% |
| Dividend Yield | 0.45% | — |
| Beta (1Y) | 0.51 | 0.16 |
| 1-Year Price Change | +7.6% | +108.3% |
| 3-Month Price Change | +12.2% | -0.7% |
| 52-Week Range | ₹585.00 – ₹1,002.40 | ₹728.00 – ₹1,814.10 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹610 Cr | ₹347 Cr |
| Quarterly Net Profit | ₹71 Cr | ₹68 Cr |
| Net Margin | 11.7% | 19.6% |
| EPS (Basic, Quarter) | ₹7.88 | ₹5.12 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Surat, Gujarat |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Aarti Pharmalabs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients, pharmaceutical intermediates, and xanthine derivatives in India and internationally. The company offers active pharmaceutical ingredients for various therapeutic areas, such as cardiovascular, anti-asthmatic, anti-cancer, anti-coagulant, anti-diabetic, arthritis, central nervous system agent, skincare, overactive bladder, calcimimetic, decongestant, anti-thalassaemic, analgesic, and ophthalmologic medications. It also provides contract development and manufacturing services for d…
Aether Industries Limited produces and sells advanced intermediates and specialty chemicals in India and internationally. It also large-scale manufacturing, contract research and manufacturing services, as well as contract/exclusive manufacturing services. The company serves its products to the chemical industry, including multinational, regional, and domestic companies in the pharmaceuticals, agrochemicals, materials science, textiles, coatings, high-performance photography, additives, and oil and gas industries. It also exports its products. Aether Industries Limited was incorporated in 2013…
Aether Industries has a market capitalisation of ₹20,196 Cr, against ₹8,060 Cr for Aarti Pharmalabs as of 9 Nov 2026, about 2.5 times the size by market cap.
Aarti Pharmalabs has a P/E of 46.2 and Aether Industries a P/E of 92 as of 9 Nov 2026.
Aarti Pharmalabs has a return on equity of 8.49% and Aether Industries 9.81%.
Aarti Pharmalabs's share price is up 7.6% over one year and Aether Industries's is up 108.3%.
Aarti Pharmalabs reported revenue of ₹610 Cr and net profit of ₹71 Cr for Q2 FY27. Aether Industries reported revenue of ₹347 Cr and net profit of ₹68 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Pharmaceutical Contract Manufacturing Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.